Sex differences in the efficacy, safety, and tolerability of omalizumab after 1 year in Maltese patients with asthma

Omalizumab has been proven to be a safe and effective drug1 in patients with severe, persistent, allergic IgE-mediated asthma. Sex differences in asthma prevalence and severity, including IgE-mediated allergic asthma, have been recognized, with women said to be more severely affected.2,3 Studies have identified that men and women respond differently to their asthma when comparing hospital admissions, quality of life, and use of inhalers.4 It is also postulated that responses to antiasthmatic drugs differ.

http://ift.tt/2mh4PWB